You searched for "globe"

905 results found

Intravitreal dexamethasone in diabetic macular oedema (DMO) - enhancing the response to anti-VEGF in non- or poor responders

This study aimed to describe the outcomes of a switch back from DEXi (dexamethasone implant) to anti-VEGF therapy in eyes that were treated temporarily with DEXi after an initial poor response to anti VEGF. Twenty-three eyes of 17 patients were...

New rules on capturing a homeless patient’s address will correct ‘major health inequality’, says the AOP

The Association of Optometrists (AOP) has welcomed an announcement by NHS England, which confirms that patients without a fixed address, including people who are homeless or rough sleeping, have a route to access NHS sight care by proving an alternative address.

Management of diabetic macular oedema (DMO)

The authors present guidelines on current diagnostic and therapeutic procedures in the management of DMO. Fluorescein angiography (FA) and optical coherence tomography (OCT) are recommended before starting treatment to help diagnose and stage DMO, and can be repeated if there...

Effects of phacoemulsification on IOP and drug use in glaucoma

For patients with comorbid cataract and primary open-angle glaucoma (POAG), guidance is lacking as to whether cataract extraction and traditional filtering surgery should be performed as a staged or combined procedure. Achieving this guidance requires an evidence-based understanding of the...

Does intravitreal bevacizumab help in diabetic retinopathy related vitreous haemorrhage?

This retrospective, interventional case series, aimed to assess the effectiveness of intravitreal bevacizumab (IVB) in vitreous haemorrhage secondary to proliferative diabetic retinopathy. The primary outcome was the rate of vitrectomy (PPV) after IVB, with secondary outcomes the number of IVB...

Fingolimod: ocular adverse effects

In this article the authors review the ocular side-effects of Fingolimod which is an oral immunomodulating drug used in the management of relapsing-remitting multiple sclerosis (RRMS). Fingolimod-associated macular oedema (FAME) is the most common ocular side-effect linked to this drug....

BELKIN Vision is pleased to announce FDA clearance for its glaucoma laser, the Eagle device

BELKIN Vision, an innovator in ophthalmic medical solutions, is pleased to announce that the US Food and Drug Administration (FDA) has granted 510(k) clearance for its glaucoma laser, the Eagle device.

PACK-crosslinking for infectious keratitis

Corneal cross-linking with riboflavin and UV-A light (CXL) is a technology that has been initially developed to treat corneal ectatic disorders [1]. Its effect in stabilising diseases such as keratoconus was reported in numerous trials with excellent long-term outcomes and...

The Diabetic Eye Screening Programme in Tanzania - The VISION 2020 LINK between Dodoma and Belfast

Rahila Bashir, Senior Remote Ophthalmic Research Image Grader, talks to Frank Sandi, Ophthalmologist at the Benjamin Mkapa Hospital (BMH), University of Dodoma in Tanzania and to Tunde Peto at Queen’s University Belfast (QUB) and Belfast Health and Social Care Trust...

Rb-NET: a network to save life and preserve vision in children in Africa

Responding to need is a key element underpinning the VISION 2020 LINKS Programme [1]. It is embedded in the process through which LINKS are established, with institutions in low- and middle-income countries (LMICs) first defining their priority areas of training...

Streamlining cataract lists: how are you managing it?

Mr Jonathan Ross, in conversation with Ms Bita Manzouri, provides a personal perspective on challenges and opportunities shaping the future of cataract surgery services across the hospital eye service. Redesigning cataract pathways in response to COVID-19 Bita Manzouri: Over the...

Addressing medical risk factors for diabetes and understanding the new systemic treatments

As global diabetes figures continue to rise, the importance of reducing the burden of macrovascular and microvascular complications of diabetes has never been so great. By 2025 it is estimated that five million people in the UK will have diabetes...